SCHEMBL21460004

SCHEMBL21460004

C=C(C)COc1ccc2nc(Cl)sc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.68
ALDH1A1 P00352 5/20 0.46
TP53 P04637 3/20 0.46
HSD17B10 Q99714 2/20 0.46
CYP3A4 P08684 1/20 0.46
TSHR P16473 1/20 0.46
MEN1 O00255 4/20 0.43
POLB P06746 2/20 0.43
CSNK1D P48730 2/20 0.43
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
CYP2D6 P10635 1/20 0.41
LMNA P02545 4/20 0.41
TDP1 Q9NUW8 3/20 0.41
KDM4E B2RXH2 3/20 0.41
PKM P14618 2/20 0.41
CA12 O43570 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748243 0.81 KMT2A (1.00) KMT2AALDH1A1TP53HSD17B10CYP3A4
SCHEMBL1748095 0.78 KMT2A (0.78) KMT2AALDH1A1TP53HSD17B10CYP3A4
SCHEMBL19782882 0.78 KMT2A (0.68) KMT2AALDH1A1TP53HSD17B10CYP3A4
SCHEMBL19776347 0.77 KMT2A (0.67) KMT2AALDH1A1TP53HSD17B10CYP3A4
SCHEMBL29481733 0.77 KMT2A (0.67) KMT2AALDH1A1TP53HSD17B10CYP3A4
SCHEMBL19776375 0.76 KMT2A (0.41) KMT2AALDH1A1MEN1RAB9ASMN1; SMN2
SCHEMBL29481746 0.76 KMT2A (0.41) KMT2AALDH1A1MEN1RAB9ASMN1; SMN2
SCHEMBL144993 0.76 KMT2A (0.69) KMT2AALDH1A1CYP3A4TSHRMEN1
SCHEMBL10531693 0.75 CA2 (0.63) KMT2AALDH1A1CYP3A4CSNK1DNPC1
SCHEMBL19776493 0.75 KMT2A (0.68) KMT2AALDH1A1TP53HSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2026-01-20 US disclosed
US-20240309019-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-09-19 US disclosed
US-11932658-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-03-19 US disclosed
CN-109689664-B Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors 百时美施贵宝公司 2022-04-15 CN disclosed
US-20210188877-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-24 US disclosed
US-20210188877-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-24 US disclosed
EP-3484894-B1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-08-19 EP disclosed
US-20190315774-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 US disclosed
US-20190315774-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315774-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS F2RL3, PARP14, PF4 KMT2A 1059/4885ALDH1A1 2845/4885TP53 1379/4885
US-20210188877-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS F2RL3, PARP14, F2R KMT2A 897/4885ALDH1A1 2558/4885TP53 1211/4885
US-11932658-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors F2RL3, PARP14, F2R KMT2A 942/4885ALDH1A1 2680/4885TP53 1325/4885
US-20240309019-A1 TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS F2RL3, PARP14, F2R KMT2A 897/4885ALDH1A1 2558/4885TP53 1211/4885
US-12528827-B2 Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors F2RL3, F2R, PF4 KMT2A 2733/4885ALDH1A1 1173/4885TP53 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.